门诊血液透析单元针对性减药质量改进研究
本研究在门诊血液透析单元(240例患者)开发并实施针对5类药物的减药工具,旨在减少多重用药。结果显示71%患者使用至少1种目标药物,88%合格患者成功减药,6个月后仅16%减药被重新处方,57%患者用药减少,无不良事件。结论认为减药工具可安全有效地减少多重用药。
要点
- 门诊血透单元可成功应用减药工具减少多重用药。
- 5类目标药物:奎宁、利尿剂、α1受体阻滞剂、PPI、他汀。
- 减药后6个月仅16%被重新处方,无不良事件。
核心结论
- 减药工具可安全应用于门诊血透单元减少多重用药并维持患者安全与满意度。
研究设计与样本
- 质量改进研究,纳入三级护理门诊血液透析单元的240例患者。
- 开发针对疗效与安全性证据不足的目标药物的减药工具并评估其效果。
主要发现
- 240例中171例(71%)使用至少1种5类目标药物。
- 应用工具后,40例合格患者中35例(88%)成功减药。
- 40种目标药物中31种(78%)完全停用。
- 6个月后,31种停用药物中仅5种(16%)被重新处方。
- 研究结束时57%患者用药数量较基线减少,未观察到不良事件。
关键数值与推荐
- 目标药物包括奎宁、利尿剂、α1受体阻滞剂、质子泵抑制剂、他汀类。
- 主要结局为4周后目标药物完全减药比例,次要结局包括6个月减药比例、人均药物数量变化及各类药物减药成功率。
临床怎么用
- 在门诊血透单元可系统筛查并应用减药工具,针对证据不足的药物进行减药。
- 减药过程中需使用药物特异性监测参数监测患者安全与满意度。
局限性
- 单中心研究,依赖患者自我报告用药及对建议的依从性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Polypharmacy in hemodialysis patients can result in adverse patient outcomes. Deprescribing tools can reduce polypharmacy, yet no method exists for an outpatient hemodialysis population. DESIGN: Quality improvement study. SETTING & PARTICIPANTS: 240 patients in a tertiary-care outpatient hemodialysis unit. QUALITY IMPROVEMENT PLAN: We aimed to: (1) develop a deprescribing tool for target medications with poor evidence for efficacy and safety, (2) determine its effectiveness in decreasing polypharmacy, and (3) monitor patient safety and satisfaction. OUTCOMES: The primary outcome was the proportion of target medications completely deprescribed after 4 weeks. Secondary outcomes were the proportion of target medications completely deprescribed after 6 months, average number of medications per patient before and after deprescription, and proportion of successful deprescriptions for each target medication. MEASUREMENTS: Number of medications deprescribed at 4 weeks and 6 months. Patient safety and satisfaction were monitored using drug-specific monitoring parameters. RESULTS: A deprescribing tool for specific medications was developed and implemented in the hemodialysis unit. 5 medication classes were selected: quinine, diuretics, α1-blockers, proton pump inhibitors, and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins). All 240 patients in the unit were screened using the deprescribing tool. There were 171 of 240 (71%) patients prescribed at least 1 of the 5 target medications, and after applying the tool, 35 of 40 (88%) eligible patients had the medications deprescribed. There were 31 of 40 (78%) target medications completely deprescribed. 6 months after the study, only 5 of 31 (16%) medications discontinued were represcribed. At the end of the study, 57% of patients were taking fewer medications than at baseline. No adverse events were observed. LIMITATIONS: Single-center study that relied on patient self-reporting of medication use and adherence to our recommendations. CONCLUSIONS: Deprescribing tools can be applied successfully in an outpatient hemodialysis unit to reduce polypharmacy while maintaining patient safety and satisfaction.
引用
- McIntyre C, McQuillan R, Bell C, et al. Targeted Deprescribing in an Outpatient Hemodialysis Unit: A Quality Improvement Study to Decrease Polypharmacy. Am J Kidney Dis. 2017. PMID: 28416321. doi:10.1053/j.ajkd.2017.02.374
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。